This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016
Experimental Hematology & Oncology Open Access 18 March 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011; 17: 20–47.
Nagafuji K, Harada M . Autologous blood stem cell transplantation-current status and issues. Fukuoka Bone Marrow Transplantation Group. Rinsho Ketsueki 1995; 36: 530–537 (Article in Japanese).
Tabata M, Kodama K, Matsuo T . Peripheral blood stem cell transplantation in patients over 65 years old with malignant lymphoma—possibility of early completion of chemotherapy and improvement of performance status. Intern Med 2001; 40: 471–474.
Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 2010; 45: 311–316.
Kameoka Y, Takahashi N, Ishizawa K, Kato Y, Ito J, Sasaki O et al. Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. Int J Hematol 2012; 96: 624–630.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253.
Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 2012; 33: 1039–1044.
Li YJ, Li ZM, Xia Y, Huang JJ, Huang HQ, Xia ZJ et al. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS ONe 2013; 8 e64158.
Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R . Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13: 575–582.
Burger R . Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother 2013; 40: 336–343.
Salem K, Brown CO, Schibler J, Goel A . Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Exp Hematol 2013; 41: 209–218.
Karin M, Greten FR . NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749–759.
Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol 2012; 91: 705–714.
Tomita N, Sakai R, Fujisawa S, Fujimaki K, Taguchi J, Hashimoto C et al. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma. Cancer Sci 2012; 103: 1518–1523.
Okada M, Sato N, Ishii K, Matsumura K, Hosono M, Murakami T . FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma. Radiographics 2010; 30: 939–957.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ariizumi, H., Saito, B., Uto, Y. et al. Predictive role of levels of soluble interleukin-2 receptor and C-reactive protein in selecting autologous PBSC transplantation for lymphoma. Bone Marrow Transplant 50, 301–303 (2015). https://doi.org/10.1038/bmt.2014.236
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.236
This article is cited by
-
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016
Experimental Hematology & Oncology (2019)